lapatinib has been researched along with gambogic acid in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (gambogic acid) | Trials (gambogic acid) | Recent Studies (post-2010) (gambogic acid) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 348 | 1 | 260 |
| Protein | Taxonomy | lapatinib (IC50) | gambogic acid (IC50) |
|---|---|---|---|
| Inhibitor of nuclear factor kappa-B kinase subunit beta | Homo sapiens (human) | 3.07 | |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 0.47 | |
| Regulator of G-protein signaling 17 | Homo sapiens (human) | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
1 review(s) available for lapatinib and gambogic acid
| Article | Year |
|---|---|
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |